[2] CJC-1295 is a tetra-substituted derivative of GHRH 1-29, the shortest functional sequence of native GHRH
How BPC-157 Works for Hair Promotes angiogenesis the formation of new blood vessels increasing blood flow to hair follicles Upregulates growth factors including VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor) Accelerates tissue repair, which is particularly beneficial for scarring alopecia or scalp damage from chemical treatments Reduces systemic inflammation that can contribute to diffuse hair thinning Supports nitric oxide pathways, improving microcirculation in the scalp What the Research Says While direct clinical trials on BPC-157 for hair loss are limited, animal studies have demonstrated significant wound healing and tissue regeneration effects

one way to quantify this is the waist-to-height ratio Waist-to-height is more effective than BMI at predicting the risk of certain diseases, especially CVD A ratio of 0.400.49 is normal, 0.500.59 is increased risk, and the highest risk is 0.60 Even at normal BMI, people with a larger waist-to-height are at greater risk of CVD and complications Knowing this may help to identify at-risk individuals in clinical practice Waist-to-height ratio is a better predictor of the presence or absence of cardiovascular disease than BMI, which really doesnt predict it. - Louis Aronne One of the good things about SELECT was the 4 years of observation in a really diverse, large population. - Donna Ryan Long-term Effects of Semaglutide Key takeaways SELECT provides 4 years of observation in a diverse population of over 17,000 people These additional long-term safety and efficacy data support the known profile of semaglutide and the wider GLP-1RA class Tolerability is well known, and there are steps that can be taken in clinical practice to manage common GI side effects With no new safety signals, SELECT reinforces this and helps to build confidence in using this class in everyday practice SELECT CVD Outcomes and Obesity Key takeaways The CV benefits seen with semaglutide may transform patient care and obesity management Even in people at very high CV risk, semaglutide may reduce heart attack, stroke, and CV death as seen in the SELECT trial There are multiple CV benefits, including improvement in heart failure and CKD, and this may result in a broadening of indications for semaglutide But semaglutide is already an option for secondary prevention of CVD, and this is translating into payer willingness to fund Results also suggest semaglutide is a powerful anti-inflammatory drug Its not just about heart attack and stroke

Jin et al
Just a quiet preparation day where you build in protein, hydration, and easy digestion before appetite possibly drops